Evidence map›Paper›PMID 41004031›Full record

ArticleInternational journal of hematology2025

Successful treatment of steroid-refractory gastrointestinal GVHD with ruxolitinib in a patient after autologous stem cell transplantation: a case report.

Duha Yahya, Mona Ayran, Ferhat Özden, Amir Hossein Abedi, Sureyya Yiğit Kaya, Hüseyin Saffet Beköz, Aslı Çakır, Senem Maral, Leylagül Kaynar

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Duha YahyaInternational School of Medicine, Istanbul Medipol University, Istanbul, Turkey. doha.abdelwahed@std.medipol.edu.tr.ORCID http://orcid.org/0000-0002-9772-3584
Mona AyranInternational School of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Ferhat ÖzdenDepartment of Pathology, International School of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Amir Hossein AbediDepartment of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Sureyya Yiğit KayaDepartment of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Hüseyin Saffet BeközDepartment of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Aslı ÇakırDepartment of Pathology, International School of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Senem MaralDepartment of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Leylagül KaynarDepartment of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGraft-versus-host disease (GVHD) is a serious immune reaction that usually occurs after allogenic stem cell transplants and can affect organs, such as skin, gastrointestinal (GI) system, and liver. The development of GVHD after autologous stem cell transplantation (auto-SCT) is rarely observed and only a few cases have been reported in the literature. CASE PRESENTATION: A 21-year-old patient who underwent auto-SCT for neurofibromatosis type 1 developed severe GI-GVHD confirmed by histopathology. She responded inadequately to systemic corticosteroids, indicating steroid-refractory disease. Subsequent addition of the JAK1/2 inhibitor ruxolitinib resulted in rapid clinical improvement.

conclusionThis clinical case scenario suggests that ruxolitinib could be a treatment option in rare cases of GVHD following auto-SCT.

Indexed as

Gastrointestinal DiseasesGraft vs Host DiseaseHematopoietic Stem Cell TransplantationPyrazolesFemaleHumansNitrilesPyrimidinesTransplantation, AutologousTreatment OutcomeYoung AdultNitrilesPyrazolesPyrimidinesruxolitinibAutologous stem cell transplantationGraft-versus-host diseaseNeurofibromatosis type 1RuxolitinibSteroid-refractory GVHD

Identifiers

PMID41004031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.